HealthLynked Corp
HLYKDrugs in Pipeline
15
Phase 3 Programs
9
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How HLYK's past catalysts played out
IDP-123 Lotion
Acne Vulgaris
MCS-2
Lower Urinary Tract Symptoms
Balsalazide Disodium
Inflammatory Bowel Disease
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
Human Papillomavirus Infection
Rifaximin
Diarrhea
IDP-122 Lotion
Plaque Psoriasis
MOA-728
Constipation
plecanatide
Chronic Idiopathic Constipation
Estradiol transdermal one 90 μL spray
Hot Flashes
EC5026 oral tablet
Parkinson's Disease (PD)
Abaloparatide Transdermal (50 mcg)
Post Menopausal Osteoporosis
VeraCept
Contraception
Danazol Once Weekly
Endometriosis
ELND005
Alzheimer Disease
Bevasiranib
Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IDP-123 Lotion | Phase 3 | Acne Vulgaris | - | - |
MCS-2 | Phase 3 | Lower Urinary Tract Symptoms | - | - |
Balsalazide Disodium | Phase 3 | Inflammatory Bowel Disease | - | - |
Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) | Phase 3 | Human Papillomavirus Infection | - | - |
Rifaximin | Phase 3 | Diarrhea | - | - |
IDP-122 Lotion | Phase 3 | Plaque Psoriasis | - | - |
MOA-728 | Phase 3 | Constipation | - | - |
plecanatide | Phase 3 | Chronic Idiopathic Constipation | - | - |
Estradiol transdermal one 90 μL spray | Phase 3 | Hot Flashes | - | - |
EC5026 oral tablet | Phase 2 | Parkinson's Disease (PD) | - | - |
Abaloparatide Transdermal (50 mcg) | Phase 2 | Post Menopausal Osteoporosis | - | - |
VeraCept | Phase 2 | Contraception | - | - |
Danazol Once Weekly | Phase 2 | Endometriosis | - | - |
ELND005 | Phase 2 | Alzheimer Disease | - | - |
Bevasiranib | Phase 2 | Macular Degeneration | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in HealthLynked Corp's drug pipeline?→
CatalystAlert tracks 15 drug candidates in HealthLynked Corp's (HLYK) pipeline across Phase 3, Phase 2. Its lead program is IDP-123 Lotion (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is HealthLynked Corp's next FDA catalyst?→
HealthLynked Corp's (HLYK) next tracked catalyst is a Phase 2 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HLYK biotech catalysts?→
Add HLYK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HealthLynked Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.